The Doctors at Pacific Northwest Retina are dedicated to providing the best, most up-to-date treatments for our patients. To this end, our doctors have participated in several clinical trials testing new drugs for Age-Related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusions, Vitreomacular Traction, and Ocular Melanoma.
Listed below are the active trials in which we are participating. Some of these trials are actively enrolling patients and others have completed enrollment and the patients are in the follow-up stage of the trial. Click on the name of the study to see more information about that specific study. If you would like to learn more about any of these trials, please send your questions to firstname.lastname@example.org or call our study coordinator at 206.215.3561.
Please note that all of our clinical trials are conducted at our Bellevue location.
New Wet AMD and Diabetic Retinopathy Trials Starting Soon
In the next several weeks Pacific Northwest Retina will be starting a Phase III clinical trial to study an investigational drug in combination with an already approved drug to treat neovascular (wet) macular degeneration, as well as a Phase III clinical trial to study an investigational drug treating patients with moderate to severe non-proliferative diabetic retinopathy (NPDR). If you are interested in learning more, please contact Renée Gagnon, Study Coordinator, at 206-215-3561.
Current clinical trials:
APL2-GA-305 (GALE) (Dry macular degeneration) – A Phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration. Participants in this study will have completed the two-year DERBY study. (Apellis Pharmaceuticals) ACTIVE – ENROLLMENT CLOSED
ISEE2008 (GATHER2) (Dry macular degeneration) – A Phase 3, multi-center, randomized, double-masked, sham-controlled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with geographic atrophy secondary to age-related macular degeneration. (Iveric Bio) ACTIVE – ENROLLMENT CLOSED